Complex Surgery Pancreas and Peri-Ampullary Region

Registration form

Dataset established by the Expert Working Group and approved by the "Stuurgroep Complexe Chirurgie - Groupe de Pilotage Chirurgie Complexe" on 30/04/2019. – Revision September 2020



Administrative patient data				
lospital:				
lealth insurance institution:				
lational number for social security (INSZ/NISS)*:		••••		
if filled out in the WBCR application, the following	variables will be complete	ed auto	maticali	ly:
Last name:				
First name:				
City:				
Country: Health insurance number:	(if possible)			
Date of birth:/ (dd/mm/yyyy)				
Date of death:/ (dd/mm/yyyy) Sex: O Male	(if applicable)			
O Female				
General information				
oid the patient undergo surgery? O No - Indication:				
NoIndication:Malignant tumour °Adenoma				
 No Indication: Malignant tumour ° Adenoma Cystadenoma 	· Noonlage (IDMNI) with I	o.u. aro	do or m	o do roto
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous 	s Neoplasm (IPMN) with l	ow gra	de or me	oderate
 No Indication: Malignant tumour ° Adenoma Cystadenoma 				
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify: Chronic pancreatitis 				
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify: 				
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify: Chronic pancreatitis Other, specify: 				
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify: Chronic pancreatitis 	ant tumour:			
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify:	ant tumour:)pancreas)			
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify: Chronic pancreatitis Other, specify: *Only to be filled out for a malignature of the primary tumour § Primary tumour § Relapse of primary 	ant tumour:)pancreas) ry tumour			
O No - Indication: O Malignant tumour o Adenoma O Cystadenoma O Intraductal Papillary Mucinous dysplasia (8453/0) O Other benign tumour, specify: O Chronic pancreatitis O Other, specify: Only to be filled out for a malignate of primary tumour of the primary tu	ant tumour:)pancreas) ry tumour ary tumour not located in	/near (peri-)pa	ncreas)
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify: Chronic pancreatitis Other, specify: Other, specify: Primary tumour § Relapse of primary Metastasis (primary Incidence date primary 	ant tumour:)pancreas) ry tumour ary tumour not located in tumour/relapse:/	/near (peri-)pa (dd/mr	ncreas) n/yyyy)
 No Indication: Malignant tumour ° Adenoma Cystadenoma Intraductal Papillary Mucinous dysplasia (8453/0) Other benign tumour, specify: Chronic pancreatitis Other, specify: Lesion to treat (in (peri- Primary tumour § Relapse of primary Incidence date primary Primary tumour/relapse 	ant tumour:)pancreas) y tumour ary tumour not located in tumour/relapse: /	/near (peri-)pa (dd/mr	ncreas) m/yyyy)
O No - Indication: O Malignant tumour o O Adenoma O Cystadenoma O Intraductal Papillary Mucinous dysplasia (8453/0) O Other benign tumour, specify: O Chronic pancreatitis O Other, specify: - Lesion to treat (in (peri- O Primary tumour o Relapse of primary - Incidence date primary - Primary tumour/relapse	ant tumour:)pancreas) y tumour ary tumour not located in tumour/relapse: /	/near (peri-)pa (dd/mr	ncreas) n/yyyy)
O No - Indication: O Malignant tumour o O Adenoma O Cystadenoma O Intraductal Papillary Mucinous dysplasia (8453/0) O Other benign tumour, specify: O Chronic pancreatitis O Other, specify: - Lesion to treat (in (peri- O Primary tumour o Relapse of primary - Incidence date primary - Primary tumour/relapse - Histological diagnosis primary	pant tumour:)pancreas) Ty tumour ary tumour not located in tumour/relapse: / clocalisation: primary tumour/relapse:	/near (. /	peri-)pa (dd/mr	ncreas) m/yyyy) apse:



	 Was the patient referred? 			
	O No			
	O Yes			
	- Referring hospital: Belgian:		or foreign:	
	If the patient did not undergo surgery, the regis	tration can be	e terminated	here.
(O Yes			
·	If the patient underwent surgery, please fill out	the following	variables	
Indicati	ion:			
	O Malignant tumour *			
	O Adenoma			
	O Cystadenoma			
	Intraductal Papillary Mucinous Neoplasm (IPMN) w (8453/0)	ith low grade	e or moderat	e dysplasia
(Other benign tumour, specify:			
	O Chronic pancreatitis	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	
	O Other, specify:			
	other, specify.	•••••	•••••	
A	* Only to be filled out for a malignant tumour:			
	 Lesion to treat (in (peri-)pancreas) 			
	O Primary tumour §			
	 Relapse of primary tumour 			
	O Metastasis (primary tumour not locate	ed in/near (pe	eri-)pancreas) §
	- Incidence date primary tumour/relapse:	/ / (0	dd/mm/yyyy)
	- Primary tumour/relapse localisation:			
	- Histological diagnosis primary tumour/relaps	se:		
	§ Only to be filled out for a primary tumour or n	netastasis, no	t a relapse:	
		cT:		cM:
	 Pathological TNM primary tumour (pTNM): 			pM:
	, and a primary carries (primary).	P	P 11 1111111	P
Type of	f FIRST diagnostic method:			
(Э ст			
(O MRI			
() PET			
(O PET/CT			
	ERCP (endoscopic retrograde cholangio-pancreato;	graphy)		
	TEUS (endoscopic ultrasound)/endoscopy			
(O Surgery (laparoscopy/laparotomy)			
-	Date:/ (dd/mm/yyyy)			
Metho	d to obtain first tissue sample for histopathological ev	aluation:		
	D ERCP (endoscopic retrograde cholangio-pancreato)			
	D EUS (endoscopic ultrasound)/endoscopy	5 -1777		
	O Surgery (laparoscopy/laparotomy/'complex' surge	rv)		
	O CT	,,		
	O MRI			
_	Date:/ (dd/mm/yyyy)			



MC/CM date:/ (dd/mm/yyyy)
Surgeon 1: number RIZIV/INAMI:
Surgeon 2: number RIZIV/INAMI: (if applicable)
Please upload the following reports without patient identification variables (e.g. name, INSZ/NISS): - MC/CM report:
Was the patient referred? O No O Yes
 Referring hospital: Belgian:
 Was the patient hospitalized at the referring hospital (before referral)? No Date of last consultation before referral:/ (dd/mm/yyyy) Yes Date of discharge at the referring hospital:/ (dd/mm/yyyy)
Patient characteristics
Height: cm
Weight at time of surgery:kg
WHO performance status at time of surgery: O - Asymptomatic, normal activity 1 - Symptomatic, but ambulant 2 - Symptomatic, bedbound <50% of the day 3 - Symptomatic, bedbound >50% of the day 4 - Completely dependent, 100% bedbound
ASA score (pre-operative risk): 1 - Healthy person 2 - Mild systemic disease, normal activity 3 - Serious systemic disease, limited activity 4 - Life-threatening illness, handicapped 5 - Dying
Comorbidity (prior to surgery) - Charlson Modified Index (not the current surgery indication!): No Yes Myocardial infarction Peripheral vascular disease Cerebrovascular disease Congestive heart failure



	Mild liver disease
	Moderate-severe liver disease
	Moderate-severe renal disease
	Chronic pulmonary disease
	Peptic ulcer
	Hemiplegia
	Dementia
	Diabetes without any damage to end-organs
	Diabetes with damage to end-organs
	Any tumour (without metastasis)
	Leukaemia (acute or chronic)
	Lymphoma
	Metastatic solid tumour
	AIDS (not just HIV positive)
_	This (not just the positive)
Is the natient c	currently (= at time of surgery) treated with antithrombotic medication?
O No	arrendy (at time or sargery) treated their arrendments are medication.
O Yes	
	B01AA: Vitamin K antagonists (e.g. warfarin)
	B01AB: Heparin group (e.g. heparin)
	B01AC: Platelet aggregation inhibitors excluding heparin (e.g. acetylsalicylic acid)
	B01AD: Enzymes (e.g. streptokinase)
	,
	B01AE: Direct thrombin inhibitors (e.g. desirudin)
	B01AF: Direct Xa inhibitors (e.g. rivaroxaban)
	B01AX: Other antithrombotic agents (e.g. dermatan sulfate)
Surgery	
•	t receive any other treatment modality before this surgical procedure?
O No	
O Yes	
	Chemotherapy
	- Start date:/ (dd/mm/yyyy)
	- Date latest treatment:/ (dd/mm/yyyy)
	- Type of chemotherapy:
	O Gemcitabine-based regimen
	O FOLFIRINOX (5-Fluorouracil, Leucovorin, Irinotecan and Oxaliplatin)-
	based regimen
	O Other, specify:
	Radiotherapy
	- Start date:/ (dd/mm/yyyy)
	- Date latest treatment:/ (dd/mm/vvvv)
	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	Prior abdominal surgery
	Prior abdominal surgery - Type of surgery:
	Prior abdominal surgery



Date of surgery:/ (dd/mm/yyyy)
Type of surgery:
O Minimally invasive surgery (MIS)
O Total laparoscopic
O Total robotic
O Hybrid (laparoscopic + robotic)
O Open
O Conversion from MIS to open surgery
- Reason for conversion:
Nomenclature code:
2 242830-242841: Pancreaticoduodenectomy
O Pancreaticoduodenectomy
O Total pancreatectomy
- Localisation lesion:
O Pancreatic head / peri-ampullary region
O Pancreatic body or tail
• 242852-242863: Hemipancreatectomy left with jejunal anastomosis of the resection plane
of the pancreas, or almost total pancreatectomy (95 pct)
2 242874-242885: Hemipancreatectomy left
242896-242900: Enucleation of a pancreatic tumour
- Localisation tumour:
Pancreatic head / peri-ampullary region
O Pancreatic body or tail
Transcreate body or tall
Simultaneous vascular resection?
O No
O Yes
☐ Superior mesenteric vein/portal vein (SMV/PV) resection
- Type of SMV/PV reconstruction:
with primary wedge-reconstruction
with primary wedge reconstruction with primary end-to-end reconstruction
with primary end-to-end reconstruction with vascular autograft interposition
with vascular altograft interposition with vascular allograft interposition
with vascular allogrant interposition with synthetic/prosthetic interposition
with synthetic/prostrictic interposition with peritoneal patch wedge-reconstruction
— /itterial resection
- Type of arterial resection:
O Hepatic artery
O Coeliac trunk
O Superior mesenteric artery (SMA)
- Type of arterial reconstruction:
O with primary wedge-reconstruction
O with primary end-to-end reconstruction
with vascular autograft interposition
with vascular allograft interposition
 with synthetic/prosthetic interposition
without reconstruction



Simultaneous of	other organ resection?
O No	
Yes	
	Colon
	Stomach
	Sur-renal gland
	Spleen
	Other, specify:
_	Other, specify.
* Only to be fill	led out for a malignant tumour:
	lual disease - resection margins:
	R0: tumour-free resection margin > 1 mm
0	
0	
9	
•	KZ. Macroscopic tumour transection
Lymphadenect	omy:
O No	
Yes	
-	Region:
	☐ Peri-tumoural
	☐ Coeliac trunk
	☐ SMA origin (superior mesenteric artery)
	☐ Para-aortic
_	Number of lymph nodes retrieved:
_	Number of lymph nodes with tumoural involvement:
-	Number of lymph flodes with tumoural involvement.
Post-surgery	•
Postoperative (complications (90 days post-op, in-hospital complications):
O No	
O Yes	
-	Type of postoperative complication(s):
	☐ Clinically relevant pancreatic fistula [cf. Bassi et al. (ISGPS), Surgery, 2017]
	O ISGPS grade B
	O ISGPS grade C
	☐ Haemorrhage [cf. Wente et al. (ISGPS), Surgery, 2007]
	○ ISGPS grade A
	○ ISGPS grade B
	○ ISGPS grade C
	☐ Delayed gastric emptying [cf. Wente et al. (ISGPS), Surgery, 2007]
	O ISGPS grade A
	O ISGPS grade B
	O ISGPS grade C
	☐ Bile leakage [cf. Koch et al. (ISGLS), Surgery, 2011]
	O ISGLS grade A
	O ISGLS grade B
	O ISGLS grade C
	☐ Intra-abdominal abscess
LL	Other, specify:



-	General Clavien-Dindo classification (90 days post-op, in-hospital complications): (https://www.baus.org.uk/patients/surgical_outcomes/grading_of_surgical_complications.aspx) O TOSGS grade 1 O TOSGS grade 2 O TOSGS grade 3a O TOSGS grade 3b O TOSGS grade 4a O TOSGS grade 4b O TOSGS grade 5
Re-operation r O No O Yes	necessary?
J 165	Type of surgery:
PI - - -	ease upload the following reports without patient identification variables: MC/CM report (if applicable):
Was the patier No Yes	Discharge date after surgery:
Did the patient O No O Yes -	In-hospital? O No O Yes Date of death:/



* Only to be filled	d out for a malignant tumour:
- Was th	ere adjuvant therapy after surgery?
O 1	No.
O Y	'es
	○ Systemic therapy
	O Radiotherapy
	O Combined therapy (systemic + radiotherapy)
	included in a clinical trial for (neo)adjuvant therapy or surgery?
O No	
O Unknov	wn
O Yes	
- E	udraCT number: or NCT number:



Registration form - version overview

Version	Changes
v1.0	Original document (28/06/2019)
v1.1	 The variable 'Nomenclature code' changed from multi- to single-select variable The variable 'Re-admission within 30 days after discharge' was moved under the variable 'Was the patient discharged after surgery during the 90-day post-op period' – option 'Yes', so that it should only be answered when the patient was discharged
v1.2	 The symbols related to the variable 'Indication' in case surgery is performed, were altered to * for malignant tumoural indications The answer option 'EUS (endoscopic ultrasound)' was expanded to 'EUS (endoscopic ultrasound)/endoscopy' for the variables 'Type of FIRST diagnostic method' and 'Method to obtain first tissue sample for histopathological evaluation' The variable 'Was the patient hospitalized at the referring hospital' was further clarified by adding: (before referral) to the question The variable 'Comorbidity (prior to surgery) - Charlson Modified Index' was further clarified by adding: 'not the current surgery indication!' The MC/CM report (if applicable), pathology report (if applicable) and surgery report are requested when re-operation was necessary The variable 'Re-admission within 30 days after discharge' was further clarified by adding: 'from the centre that performed the surgery' The variable 'Was there adjuvant therapy after surgery?' and the variable to
v1.3	 specify the adjuvant therapy were moved further down the document For the nomenclature code '242830-242841: Pancreaticoduodenectomy', the answering option 'Whipple' has been changed to 'Pancreaticoduodenectomy' and '242896-242900: Enucleation of a pancreatic tumour', the answering option 'Pancreatic tail' has been changed to 'Pancreatic body or tail' The option 'without reconstruction' has been added in case of a SMV/PV resection A question has been added regarding the type of reconstruction in case of an arterial resection The definitions corresponding to R0 and R1 resection margins have been changed: From 'R0: no residual disease' to 'R0: tumour-free resection margin > 1 mm' From 'R1 indirect: R0 with magnitude of resection margin < 1 mm' to 'R1 indirect: tumour-free resection margin' The question on lymph node retrieval has been changed from 'number of locoregional lymph nodes retrieved' to 'number of lymph nodes retrieved' The question on the number of involved lymph nodes has been changed from 'number of metastatic loco-regional lymph nodes' to 'number of lymph nodes with tumoural involvement'
v2.0	 Added additional question in case of malignant indication (lesion to treat): primary tumour, relapse of primary tumour or metastasis Added specific variables from the MOC/COM cancer registration (bijlage/annexe 55) in case of a malignant indication: incidence date primary tumour/relapse, primary tumour/relapse localization, histological diagnosis primary tumour/relapse, cTNM and pTNM in case of primary tumour or

Belgian Cancer RegistryComplex Surgery PancreasRegistration formVersion 2.0 (29/09/2020)10

metastasis
- MC/CM date

- RIZIV numbers surgeon(s)



Complex Surgery Pancreas Registration form Version 2.0 (29/09/2020) 11